Načítá se...
SGLT2 Inhibitors May Predispose to Ketoacidosis
CONTEXT: Sodium glucose cotransporter 2 (SGLT2) inhibitors are antidiabetic drugs that increase urinary excretion of glucose, thereby improving glycemic control and promoting weight loss. Since approval of the first-in-class drug in 2013, data have emerged suggesting that these drugs increase the ri...
Uloženo v:
| Vydáno v: | J Clin Endocrinol Metab |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Endocrine Society
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4525004/ https://ncbi.nlm.nih.gov/pubmed/26086329 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jc.2015-1884 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|